Views & Analysis Calls to end the silent epidemic of PTHP Campaigners want to raise awareness of post-traumatic hypopituitarism following a head injury.
News Parabilis prices IPO at an ambitious $475 million Parabilis has set the terms of its IPO, seeking to raise a hefty $475m for phase 3 trials of its lead drug for desmoid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
